Considerations for Chemotherapy-Induced Neutropenia Prophylaxis

EP: 1.Facts About Chemotherapy-Induced Neutropenia

EP: 2.Chemotherapy-Induced Neutropenia: Impact on Cancer Care

EP: 3.Monitoring for Chemotherapy-Induced Neutropenia

Now Viewing

EP: 4.Considerations for Chemotherapy-Induced Neutropenia Prophylaxis

EP: 5.Chemotherapy-Induced Neutropenia Prophylaxis: Standard of Care

EP: 6.CIN Prophylaxis: Treating With G-CSFs

EP: 7.Plinabulin With G-CSF Treatment for CIN Prophylaxis

EP: 8.CIN Prophylaxis: NCCN’s Reactions to COVID-19

EP: 9.Chemotherapy-Induced Neutropenia: Financial Burden

EP: 10.Health Plans React to Chemotherapy-Induced Neutropenia

EP: 11.Reducing the Risk of Chemotherapy-Induced Neutropenia

EP: 12.At-Home Administration of CIN Prophylaxis

EP: 13.Coverage for Chemotherapy-Induced Neutropenia

Lee Schwartzberg, MD, FACP: It’s interesting that when you do careful analysis of various chemotherapy regimens across the board, the cycle that is at greatest risk for CIN [chemotherapy-induced neutropenia] and FN [febrile neutropenia] is the first cycle of any regimen. That may be because the bone marrow has not been primed to expand its neutrophil precursors until there is an insult to it, which occurs with myelosuppressive chemotherapy. Therefore, it’s important for clinicians to think about prophylaxis against neutropenia before they start a new regimen, not afterward.

In fact, about 50% of episodes of febrile neutropenia occur with the first cycle of therapy regardless of which treatment you’re giving. A clinician should be evaluating the risk of myelosuppression from the chemotherapy, along with the patient risk factors, along with tumor risk factors, to make a decision whether prophylaxis against CIN should be given with the first cycle of any new regimen.

If a patient is to get a myelosuppressive chemotherapy, the clinician should think about prophylaxis against CIN, and we have prophylactic measures that are effective. Keeping the neutrophil count high, above that 1000 [per μL] point, through the entire cycle of therapy and avoiding the nadir count, which occurs with myelosuppressive chemotherapy at some predictable time, usually in the middle of the cycle, is the goal, because if we can do that effectively then the patient will not be at risk for febrile neutropenia. The patient will not be at risk for all the complications of neutropenia, including hospitalization potentially, and the patient will not be at risk for a dose delay or a dose modification. Therefore, the resource utilization could be dramatically lower if prophylaxis is appropriately employed prior to initiating a new regimen of myelosuppressive chemotherapy.